| Literature DB >> 34327226 |
Shi-Bing Liang1,2, Ning Liang1,3, Fan-Long Bu1, Bao-Yong Lai1,4, Ya-Peng Zhang1, Hui-Juan Cao1, Yu-Tong Fei1, Nicola Robinson1,5, Jian-Ping Liu1,6.
Abstract
The objectives of this study are to conduct a comprehensive literature search and bibliometric analysis to identify the breadth and volume of pharmacological and clinical studies on pine pollen (Pinus pollen) and to identify the potential effects and the use of pine pollen. Three Chinese electronic databases and two English electronic databases were searched for pharmacological and clinical studies on pine pollen. Data were extracted and analyzed and included publication year, authors, study type, pharmacological research topics or clinical diseases/conditions, usage and type of preparation, authors' conclusions, and adverse effects. Of 239 publications identified, 180 were pharmacological studies, 37 were clinical trials, and 22 were reviews. Numbers of publications increased particularly from 2004 onward. The top 10 most frequent topics in pharmacological studies were immune regulation, antisenility, antioxidation, liver protection, inhibiting prostate hyperplasia, inhibiting tumor cell proliferation, lowering blood glucose, lowering blood lipids, antifatigue, and improving intestinal function. The top 10 most frequent clinical diseases treated or where pine pollen was used as an adjuvant were bedsores, diaper dermatitis, hyperlipidemia, oral mucositis, eczema, hyperplasia of prostate, hypertension, prostatitis, type 2 diabetes mellitus, and radiodermatitis. Eight trials reported no adverse events associated with pine pollen, one reported mild gastrointestinal reactions, but symptoms disappeared without special management. There have been an increasing number of publications on pine pollen during the past 20 years. Pharmacological studies have shown many potential benefits, and clinical studies have indicated some positive effects when it is either used as a single herb or as an adjuvant to treat disease. Its use as a topical agent, especially for skin diseases, was notable.Entities:
Keywords: Bibliometric analysis; Chinese herbal medicine; Pinus pollen; pine pollen; skin disease
Year: 2020 PMID: 34327226 PMCID: PMC8318335 DOI: 10.4103/wjtcm.wjtcm_4_20
Source DB: PubMed Journal: World J Tradit Chin Med ISSN: 2311-8571
Figure 1:The flowchart of study searching and selection
Figure 2:Trends in the year of publications on pine pollen
The top 10 most frequent research topics being studied on pine pollen’ pharmacology
| Rank | Study topics | |
|---|---|---|
| 1 | Immune regulation | 36 (20.0) |
| 2 | Antiaging | 25 (13.89) |
| 3 | Antioxidation | 20 (11.11) |
| 4 | Liver protection | 16 (8.89) |
| 5 | Inhibiting tumor cell proliferation | 15 (8.33) |
| 6 | Inhibiting prostate hyperplasia | 12 (6.67) |
| 7 | Antifatigue | 8 (4.45) |
| 8 | Lowering blood glucose | 7 (3.89) |
| 9 | Lowering blood lipids | 6 (3.33) |
| 10 | Improving intestinal function | 6 (3.33) |
| Total (top 10 topics) | 151 (83.89) | |
| Percentage=( | ||
Characteristics of the included 37 clinical studies
| Study ID | Study type | Diseases | Sample size | Ages | Intervention | Treatment sessions | Outcome measurements | Adverse events | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ba | RCT | Bedsores | 23 | 23 | 45-69 years | 45-69 years | Pine pollen, topical; sensitive antibiotics, oral or intravenous | 0.5% iodophor, topical; sensitive antibiotics, oral or intravenous | 7 days | Effective rate | Not reported |
| Li, 2013[ | RCT | Bedsores | 28 | 28 | 46-84 years | 46-83 years | Pine pollen, topical; Long Zhu ointment, topical | Moisture-exposed bum ointment, topical | 4 weeks | PUSH tool; wound healing time | Not reported |
| Zhang | RCT | Bedsores | 33 | 30 | 20-85 years | 18-81 years | Pine pollen, topical; silver sulfadiazine, topical | Sterile Vaseline, topical | Not reported | Wound healing time; wound healing time index | Not reported |
| Cai, 2014[ | RCT | Diaper dermatitis | 30 | 30 | Not reported | Not reported | Pine pollen, topical; iodophor, topical | Iodophor, topical | Not reported | Effective rate; wound healing time | Not reported |
| Chen and Zhang, 2013[ | RCT | Diaper dermatitis; eczema | 100 | 100 | Not reported | Not reported | Pine pollen, topical | Talcum powder, topical | 3 months | Effective rate; adverse events | None |
| Ouyang | RCT | Eczema | 50 | 50 | 7-45 days | 7-45 days | Pine pollen, topical | Erythromycin Ointment, topical | 10 days | Effective rate; adverse events | None |
| Huang | RCT | Hyperlipidemia | 50 | 50 | ≧40 years | ≧40 years | Antibang capsules (the main ingredient is pine pollen), oral | Placebo, oral | Not reported | Effective rate; blood lipid level (TG, HDL-C and TC) | Not reported |
| Wang and Qian, 2009[ | RCT | Hypertension | 54 | 53 | 50.20±6.33 years | 48.89±4.36 years | Pine pollen, oral | Placebo, oral | Not reported | Effective rate; blood pressure changes; blood lipid level | Not reported |
| Fang | RCT | Type 2 diabetes mellitus | 35 | 30 | 30-72 years | 32-70 years | Pine pollen, oral; Metformin, oral | Metformin, oral | 12 weeks | FBG; PBG; HbAlc; insulin level; HOMA-IR; HOMA-β; adverse events | Yes |
| Fang | RCT | Type 2 diabetes mellitus | 30 | 30 | ≧18 years | ≧18 years | Pine pollen capsules, oral | Conventional western medicine, oral | 8 weeks | Effective rate; blood sugar levels; HbAlc; adverse events | None |
| Gong and Li, 2012[ | RCT | Hyperplasia of prostate | 123 | 83 | 50-82 years | 53-81 years | Pine pollen combined with Ruanji Tongbi prescription, oral | Finasteride, oral | 3 months | Effective rate; adverse events | None |
| Lu | RCT | Oral mucositis | 40 | 40 | Not reported | Not reported | Pine pollen combined with sesame oil, topical | Compound gargle solution chlorhexidine gluconate, topical | 5 days | Effective rate | Not reported |
| Liu, 2013[ | RCT | Oral mucositis | 188 | 184 | 42.0±3.0 years | 42.0±3.0 years | Pine pollen, topical; pine pollen tablet, oral | Metronidazole, Prednisone acetate, Vitamin B2, topical; metronidazole, Vitamin B2, oral | 6 months | Effective rate | Not reported |
| Gu | RCT | Oral mucositis | 45 | 45 | 28-71 years | 28-71 years | Pine pollen, topical; honey, topical; oxygen blowing | Compound gargle solution chlorhexidine gluconate, topical | 5 days | Effective rate; wound healing time | Not reported |
| Liao and Zhai, 2013[ | RCT | Radiodermatitis | 40 | 40 | 27-68 years | 27-68 years | Pine pollen, topical | Moisture exposed burn ointment, topical | 2 weeks | Wound healing time | Not reported |
| Du | CCT | Hyperlipidemia | 50 | 50 | 56.30±5.63 years | 56.18±5.92 years | Pine pollen supercritical CO2 extract soft capsule, oral | Placebo, oral | 30 days | Effective rate; adverse events | None |
| Fan, 2006[ | CCT | Hyperlipidemia | 50 | 50 | 18-68 years | 18-65 years | Pine pollen, oral | Blank | 45 days | Effective rate; TC; TG; hemogram; liver and kidney function; adverse events | None |
| Hu and Zhu, 2007[ | CCT | Hypertension | 54 | 53 | 50.20±6.33 years | 48.89±4.36 years | Pine pollen capsule, oral | Placebo, oral | 6 weeks | Effective rate; blood pressure level; blood lipid level; symptom change | Not reported |
| Zhang | CCT | Adverse effect of chemotherapy | 31 | 31 | 55.41±2.47 years | 54.26±2.45 years | Pine pollen, oral | Placebo, oral | 5 days | Adverse events (the number in the experimental group was significantly lower than that in the control group); quality of life | Yes |
| Wen | CCT | Constipation | 56 | 57 | 53.8 years | 52.9 years | Pine pollen tablet, oral | Placebo, oral | 10 days | Stool frequency; stool consistency; adverse events | None |
| Yang, 2012[ | CCT | Disorders of skin | 23 | 23 | 67-94 years | 67-94 years | Pine pollen, topical; baby wipes, topical | Zinc oxide ointment, topical | Not reported | Effective rate | Not reported |
| Jin and Zheng, 2000[ | Case series | Diaper dermatitis | 72 | 0-3 years | Pine pollen combined with talcum powder, topical | 3 days | Effective rate; adverse events | None | |||
| Zhu, 1989[ | Case series | Diaper dermatitis | 87 | ≧1 years | Pine pollen, topical | Not reported | Effective rate | Not reported | |||
| Hong, 1966[ | Case series | Diaper dermatitis | 15 | Not reported | Pine pollen, topical | 6-7 days | Degree of satisfaction | Not reported | |||
| Jiao, 2008[ | Case series | Bedsores | 34 | 48-87 years | Pine pollen combined with sesame oil, topical; sensitive antibiotics, oral or intravenous; high protein and high vitamin diet | 7 days | Effective rate; adverse events | None | |||
| Zhou, 2003[ | Case series | Bedsores | 30 | 65-92 years | Pine pollen, topical | 4-6 weeks | Effective rate | Not reported | |||
| Liu, 2014[ | Case series | Prostatitis | 68 | 25-60 years | Pine pollen tablet combined with terazosin tablet, oral | 6 weeks | NIH-CPSI scores; EPS-WBC | Not reported | |||
| Wang, 2006[ | Case series | Prostatitis; Hyperplasia of prostate | 50 | 45-95 years | Pine pollen combined with Ba Zheng San prescription, oral | Not reported | Effective rate | Not reported | |||
| Bai, 2010[ | Case series | Hyperplasia of prostate | 53 | <50 years: 6 patients; 50-78 years: 47 patients | Pine pollen combined with Saren Garidi (Mongolian medicine), oral | 10 days | Effective rate | Not reported | |||
| Huang, 1998[ | Case series | Hyperlipidemia | 32 | 30-50 years | Pine pollen tablet, oral | 4 months | Effective rate | Not reported | |||
| Liu | Case series | Eczema | 48 | 7-66 years | Pine pollen, topical (chronic eczema: oral and topical) | 10 days | Effective rate | Not reported | |||
| An and Wang 2013[ | Case series | Senility | 100 | 50-83 years | Pine pollen capsule, oral; physical therapy | 2 months | Effective rate; TC; TG; HDL-C; Apo AI; Apo B; HYP; Ca2+ | Not reported | |||
| Zhang | Case series | Localized edema | 36 | 35-68 years | Pine pollen, topical; ultraviolet ray irradiation | 3-5 days | The degree of healing | Not reported | |||
| Xiao, 1982[ | Case series | Chronic ulcer of skin | 100 | ≦68 years | Pine pollen, topical | 10-30 days | Effective rate; wound healing time | Not reported | |||
| Zhang | Case series | Radio dermatitis | 8 | Not reported | Pine pollen combined with Aloe Vera, topical | 4-21 days | Wound healing time | Not reported | |||
| Guo | Case report | Bedsores | 1 | 72 years | Pine pollen, topical | 6 days | Cured | Not reported | |||
| Zhang, 1997[ | Case report | Chicken pox | 1 | 12 years | Pine pollen, topical | 2 days | Cured | Not reported | |||
E: Experimental group, C: Control group, TG: Triglyceride, TC: Serum total cholesterol, HDL-C: High-density lipoprotein cholesterol, HbAlc: Glycated hemoglobin, FBG: Fasting blood-glucose, PBG: Postprandial blood glucose, HOMA-IR: Homeostasis model assessment-insulin resistance; HOMA-β: Homeostasis model assessment-β, NIH-CPSI: National Institute of Health-Chronic Prostatitis Symptoms Index, EPS-WBC: Expressed prostatic secretions-white blood cells; Apo AI: Apolipoprotein AI, Apo B: Apolipoprotein B, HYP: Hydroxyproline, RCT: Randomized controlled trial, CCT: Controlled clinical trial, PUSH: Pressure ulcer scale for healing
The top 10 most frequent diseases being treated with pine pollen alone or as an adjuvant therapy
| Rank | Disease | ICD-10 codes | Type and quantity of research | Total (%) | |||
|---|---|---|---|---|---|---|---|
| RCTs | CCTs | Case series | Case reports | ||||
| 1 | Bedsores | L89 | 3 | 0 | 2 | 1 | 6 (16.22) |
| 2 | Diaper dermatitis | L22 | 2 | 0 | 3 | 0 | 5 (13.51) |
| 3 | Hyperlipidemia | E78 | 1 | 2 | 1 | 0 | 4 (10.81) |
| 4 | Oral mucositis | K12 | 3 | 0 | 0 | 0 | 3 (8.11) |
| 5 | Eczema | L20 | 2 | 0 | 1 | 0 | 3 (8.11) |
| 6 | Hyperplasia of prostate | N40 | 1 | 0 | 2 | 0 | 3 (8.11) |
| 7 | Hypertension | I10 | 1 | 1 | 0 | 0 | 2 (5.41) |
| 8 | Prostatitis | N41 | 0 | 0 | 2 | 0 | 2 (5.41) |
| 9 | Type 2 diabetes mellitus | E11 | 2 | 0 | 0 | 0 | 2 (5.41) |
| 10 | Radiodermatitis | L58 | 0 | 1 | 1 | 0 | 2 (5.41) |
Percentage=(n/37)%: Chen and Zhang, 2013[ studied diaper dermatitis and eczema in the same study; Wang, 2006[ studied prostatitis and hyperplasia of prostate in the same study. ICD-10: International classification of diseases 10th revision, RCTs: Randomized controlled trials, CCTs: Controlled clinical trials